4/A: Chromocell Therapeutics Executive Corrects Stock Transaction Report

Francis Knuettel II, CEO, President, CFO, Treasurer, and Secretary of Chromocell Therapeutics, files an amended Form 4 to correct a previous report regarding stock options acquired by Camden Capital LLC.

Summary

• Francis Knuettel II, an officer of Chromocell Therapeutics Corp, filed an amended Form 4 with the SEC.
• The amendment corrects a previous filing from February 23, 2024, which incorrectly stated that Camden Capital LLC disposed of 2,778 shares.
• The corrected filing indicates that Camden Capital LLC actually acquired 2,778 shares of Chromocell's common stock at an exercise price of $22.68 per share following the grant of stock options.
• These options became exercisable upon the closing of Chromocell's initial public offering.
• Knuettel, as the manager of Camden Capital LLC, is deemed the beneficial owner of these securities.

Sentiment

Score: 7

Explanation: The document is a routine correction of a previously filed form, indicating standard corporate governance practices. The sentiment is neutral to slightly positive as it reflects transparency and adherence to regulatory requirements.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, ensuring transparency in the market.

Stakeholder Impact

• The correction of the Form 4 filing ensures accurate information is available to shareholders regarding insider transactions.

Key Dates

Keywords

Form 4, amendment, stock options, Chromocell Therapeutics, Camden Capital LLC, beneficial ownership, Francis Knuettel II